• Apogee Therapeutics CEO Michael Thomas Henderson cut his stake through a 20,000-share sale on July 8 at USD 133.63.
• He also disposed of 75,046 shares on July 10 in a transaction reported at USD 0.
• Henderson reported 920,941 shares owned following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082758), on July 10, 2026, and is solely responsible for the information contained therein.